We are a national and international leader in research and clinical trials for epilepsy.

The findings from our extensive research are translated into the care of our patients, providing rapid access to the latest treatment alternatives.

Current and recent projects include:

• 
  Participating in the pivotal clinical trials of five of the nine antiepileptic drugs brought to market in the past 13 years (lamotrigine, topiramate, felbamate, tiagabine, and levetiracetam)
  


• Phase 2 and 3 trials of drugs presently under development
  


• Investigator-initiated studies to compare antiepileptic drugs in terms of efficacy and tolerability
  
  
• Use of image guidance to co-register not only MRI but nuclear medicine and EEG data for the safest possible seizure surgery
  


• Protocols with Case Engineering to study methods of seizure detection
  


• Researching methods to predict seizures so that treatments could be developed to head off a seizure before it begins; the project is being done in collaboration with Cleveland-based industry and NINDS

---

Current Clinical Trials

A Double-Blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects With Partial Onset Seizures.
Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of BRV in the conversion of partial onset seizure patients from combination treatment to monotherapy.

Visual Field Assessment With Subjects Who Receive Either Lyrica Or Sugar Pills
Epileptic partial seizure subjects will be assigned to take either Lyrica 300 mg per day or placebo, which is a sugar pill with no active ingredients in it for 3 months. By the end of the treatment the person's visual field test results will be compared to the one test collected at the beginning, prior to taking the study drug to see if there are any changes.